Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 38 Colorectal Neoplasms 18 Small Cell Lung Carcinoma 8 Neoplasms 8 Stomach Neoplasms 7 Neoplasm Metastasis 5 Biliary Tract Neoplasms 5 Sarcoma, Ewing 4 Rhabdomyosarcoma 4 Recurrence 4 Osteosarcoma 4 Rectal Neoplasms 3 Ovarian Neoplasms 3 Cholangiocarcinoma 3 Triple Negative Breast Neoplasms 2 Solid Tumor 2 Neuroblastoma 2 Nasopharyngeal Carcinoma 2 Metastatic Pancreatic Adenocarcinoma 2 Head and Neck Neoplasms 2 Glioma 2 Glioblastoma 2 Gastrointestinal Neoplasms 2 Fallopian Tube Neoplasms 2 Esophageal Neoplasms 2 Wilms Tumor 1 Weight Loss 1 Somatostatinoma 1 Solid Tumor Cancer 1 Small Cell Lung Cancer Extensive Stage 1

Interventions

Cisplatin 12 Everolimus 10 Nivolumab 8 Etoposide 8 Temozolomide 6 Carboplatin 6 atezolizumab 5 Irinotecan 5 Ipilimumab 5 Fluorouracil 5 Bevacizumab 5 pembrolizumab 4 lutetium Lu 177 dotatate 4 Capecitabine 4 avelumab 3 Paclitaxel 3 IFL protocol 3 surufatinib 2 sintilimab 2 gallium Ga 68 dotatate 2 dostarlimab 2 cabozantinib 2 belinostat 2 azaspirane 2 Topotecan 2 Radiosurgery 2 Positron Emission Tomography Computed Tomography 2 PE regimen 2 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Magnetic Resonance Imaging 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × irinotecan sucrosofate × Clear all

NCT03837977 2024-12-30

NET02

The Christie NHS Foundation Trust

Phase 2 Completed

Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡